DUBLIN–(BUSINESS WIRE)–The “Global Allergy Diagnostics and Therapeutics Market 2022-2028” report has been added to ResearchAndMarkets.com’s offering.
The global allergy diagnostics and therapeutics market is anticipated to grow at a substantial CAGR of 11.4% during the forecast period. The rising environmental pollution levels such as air pollution, and allergens cause severe respiratory diseases and other diseases.
For instance, according to the UN environment program(UNEP), Air pollution is the greatest environmental threat to public health globally and accounts for an estimated 7 million premature deaths every year. Around four million people died in 2019 from exposure to fine particulate outdoor air pollution, with the highest death rates occurring in Asia and Eastern Europe.
The global allergy diagnostics and therapeutics market is segmented based on products, drug class, and end-user. Based on products the market is sub-divided into instruments and consumables. Based on drug class the market is bifurcated into antihistamines, decongestants, corticosteroids, mast cell stabilizers, leukotriene inhibitors, nasal anticholinergic, immunomodulators, auto-injectable epinephrine, and immunotherapy.
Based on end-user the market is sub-segmented into diagnostic labs, hospitals, and academic research institutions. The hospital segment is anticipated to grow at the fastest rate, as hospitals assist the patients to take medical assistance under the observation of experienced surgeons.
The increasing number of allergic patients along with growing awareness regarding the various benefits and facilities provided in hospitals is considered a prime factor that is supporting the growth of the hospital segment.
Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America dominates the market and is expected to continue its presence over the forecast period.
The growth can be attributed to the increasing number of food allergy patients and increasing adoption of allergy diagnostics and therapeutics solutions in allergy diagnosis as a result, the demand for allergy diagnostics and therapeutics for determining allergy presence is set to increase over the coming years, which has contributed to the growth of the market in the North America region.
For instance, according to FARE peanuts were the most commonly specifically identified food causing anaphylaxis allergy accounting for 26% of the cases. Also common were egg allergies, crustacean allergies (e.g., allergies to shrimp or lobster), and dairy allergies, making up, respectively, 7 %, 6 %, and 5 %
The major companies serving the global allergy diagnostics and therapeutics market are Hitachi Chemical Diagnostics, Inc., HOB Biotech GroupCorp., Ltd., Hycor Biomedical, LLC, Lincoln Diagnostics, Inc., Omega Diagnostics Group PLC, and others.
The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market.
For instance, in 2020 HYCOR Biomedical and Changsha Haike Biotechnology Co., Ltd. had done registration with Hunan Medical Products Administration (HMPA) for the ALLEOS 2000 allergy testing system.
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Thermo Fisher Scientific, Inc.
184.108.40.206. Financial Analysis
220.127.116.11. SWOT Analysis
18.104.22.168. Recent Developments
3.1.2. Stallergenes Greer PLC
3.1.3. Siemens AG
3.1.4. BioMerieux SA
3.1.5. Hitachi Chemical Diagnostics, Inc.
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Determinants
5. Market Segmentation
5.1. Global Allergy Diagnostics and Therapeutics Market, by Products
5.2. Global Allergy Diagnostics and Therapeutics Market, by Drug class
5.2.4. Mast Cell Stabilizers
5.2.5. Leukotriene Inhibitors
5.2.6. Nasal Anticholinergic
5.2.8. Auto Injectable Epinephrine
5.3. Global Allergy Diagnostics and Therapeutics Market, by End-User
5.3.1. Diagnostic Labs
5.3.2. Hospitals and Clinics
5.3.3. Academic Research Institutions
6. Regional Analysis
6.1. North America
6.1.1. United States
6.2.6. Rest of Europe
6.3.4. South Korea
6.3.5. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Allergan PLC
7.2. ACON Laboratories, Inc.
7.3. AESKU.GROUP GmbH
7.4. Astra Biotech GmbH
7.5. Allergy Therapeutics PLC
7.6. bioMerieux SA
7.7. Danaher Corp.
7.8. Eurofins Scientific
7.9. HAL Allergy Group
7.10. Hitachi Chemical Diagnostics, Inc.
7.11. HOB Biotech GroupCorp., Ltd.
7.12. Hycor Biomedical, LLC
7.13. Immunodiagnostic Systems Holdings PLC
7.14. Lincoln Diagnostics, Inc.
7.15. NEOGEN Corp
7.16. Omega Diagnostics Group PLC
7.17. PerkinElmer, Inc.
7.18. Quest Diagnostics, Inc.
7.19. R-Biopharm AG
7.20. Romer Labs Division Holding
7.21. Siemens AG
7.22. Stallergenes Greer PLC
7.23. Thermo Fisher Scientific, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/352k5v
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900